NORTH CHICAGO, Ill., May 15, 2013 /PRNewswire/ -- AbbVie today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at the upcoming 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 - June 4, Chicago. Data being presented include the results from two clinical trials evaluating the safety and efficacy of ABT-199, a BCL-2 selective inhibitor, in chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL).
Meeting abstracts are available today at http://chicago2013.asco.org/abstracts.
"These presentations further solidify our commitment to addressing the unmet need for new therapies that can improve on current treatment options for patients with cancer," said Gary Gordon, M.D., divisional vice president, oncology clinical development, AbbVie. "With our pioneering research, we are breaking new ground in some of the most widespread and difficult-to-treat cancers."
Presentation Details:
ABT-199
Updated Results of a Phase I First-In-Human Study of the BCL-2 Inhibitor ABT-199 (GDC-0199) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL); J.F. Seymour, et al.; Abstract 7018; Poster Discussion Session; June 1, 2013; 8:00 a.m.-12:00 p.m.
Updated Results of a Phase I First-In-Human Study of the BCL-2 Inhibitor ABT-199 (GDC-0199) in Patients with Relapsed/Refractory (R/R) non-Hodgkin's Lymphoma (NHL); M.S. Davids, et al.; Abstract 8520; Oral Presentation; June 3, 2013; 11:30 a.m.-1:30 p.m.
Elotuzumab
A Phase I/II Study of Elotuzumab (Elo) plus Lenalidomide/Dexamethasone in Relapsed/Refractory (R/R) Multiple Myeloma: Updated Phase II results and Phase I/II long-term safety; S. Lonial, et al.; Abstract 8542; Poster Discussion Session; June 3, 2013; 1:15 p.m.-5:15 p.m.
ABT-888 (Veliparib)
A Phase I Study of Veliparib (ABT-888) in Combination with Carboplatin and Gemcitabine in Subjects with Advanced Solid Tumors; K. M. Bell-McGuinn, et al.; Abstract 2485; Poster Discussion Session; June 3, 2013; 8:00 a.m.-11:45 a.m.
ABT-806
A phase I and Biodistribution Study of ABT-806i, an 111 Iindium-Labeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806; H.K. Gan, et al.; Abstract 2520; Poster Discussion Session; June 4, 2013; 8:00 a.m.-12:30 p.m.
About ABT-199
ABT-199 is a selective inhibitor of B-cell lymphoma-2 (BCL-2) proteins. The B-cell lymphoma 2 gene prevents apoptosis of some cells including lymphocytes, and can be highly expressed in cancers in the lymph nodes, spleen, and other organs of the immune system. As a BH3-mimetic, ABT-199 is designed to block the function of the BCL-2 protein by restoring the communication system that tells cancer cells to self-destruct. Jointly developed by AbbVie and Genentech, the companies are pioneering BCL-2 research with ABT-199, which is currently in Phase 1/1b clinical trials for the treatment of CLL, the most common leukemia in the United States, and several other cancers.
The U.S. Food and Drug Administration (FDA) recently accepted AbbVie's amended clinical trial protocols for studies of ABT-199 in patients with CLL and enrollment for ABT-199 clinical trials in CLL, NHL and multiple myeloma has been re-instated. AbbVie and Genentech expect to move ABT-199 into later-stage clinical trials in the near future.
About Elotuzumab
Elotuzumab is a humanized monoclonal antibody that targets against CS1, a cell-surface glycoprotein that is highly expressed on multiple myeloma cells. Two Phase 3 studies of elotuzumab in combination with lenalidomide and low-dose dexamethasone at a dose of 10 mg/kg are ongoing in patients with newly-diagnosed (ELOQUENT1) and relapsed/refractory multiple myeloma (ELOQUENT2). Elotuzumab is being jointly developed by AbbVie and Bristol-Myers Squibb.
About ABT-888 (Veliparib)
Veliparib is an investigational oral poly (adenosine diphosphate [ADP]–ribose) polymerases (PARPs) inhibitor being evaluated in multiple tumor types. PARP is a naturally occurring enzyme in the body that repairs damage to DNA, and contributes to chemotherapy resistance in cancer cells. Discovered and developed by AbbVie researchers, ABT-888 (veliparib) is being developed to increase the effectiveness of common DNA-damaging therapies like chemotherapy or radiation. Veliparib is currently being studied in more than a dozen cancers and tumor types, including Phase 2 studies in a variety of cancers, including breast, ovarian, non small-cell lung and gastrointestinal cancers.
About ABT-806
ABT-806i is an immunoradiopharmaceutical formed by labeling monoclonal antibody ABT‑806 with indium 111 (111In). The antibody portion of the radiopharmaceutical, ABT-806, is a humanized antibody specific for an epitope of EGFR; and epitope that is exposed in deletion variant EGFRde2-7 (EGFRvIII) or when wild-type EGF receptors are amplified, overexpressed, or activated. This epitope provides for the opportunity to use ABT-806i as an imaging agent for the identification and characterization of solid tumor malignancies expressing EGFR, including those expressing deletion variant EGFRde2-7. ABT-806 was in-licensed by AbbVie from Life Science Pharmaceuticals.
Meeting abstracts are available today at http://chicago2013.asco.org/abstracts.
"These presentations further solidify our commitment to addressing the unmet need for new therapies that can improve on current treatment options for patients with cancer," said Gary Gordon, M.D., divisional vice president, oncology clinical development, AbbVie. "With our pioneering research, we are breaking new ground in some of the most widespread and difficult-to-treat cancers."
Presentation Details:
ABT-199
Updated Results of a Phase I First-In-Human Study of the BCL-2 Inhibitor ABT-199 (GDC-0199) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL); J.F. Seymour, et al.; Abstract 7018; Poster Discussion Session; June 1, 2013; 8:00 a.m.-12:00 p.m.
Updated Results of a Phase I First-In-Human Study of the BCL-2 Inhibitor ABT-199 (GDC-0199) in Patients with Relapsed/Refractory (R/R) non-Hodgkin's Lymphoma (NHL); M.S. Davids, et al.; Abstract 8520; Oral Presentation; June 3, 2013; 11:30 a.m.-1:30 p.m.
Elotuzumab
A Phase I/II Study of Elotuzumab (Elo) plus Lenalidomide/Dexamethasone in Relapsed/Refractory (R/R) Multiple Myeloma: Updated Phase II results and Phase I/II long-term safety; S. Lonial, et al.; Abstract 8542; Poster Discussion Session; June 3, 2013; 1:15 p.m.-5:15 p.m.
ABT-888 (Veliparib)
A Phase I Study of Veliparib (ABT-888) in Combination with Carboplatin and Gemcitabine in Subjects with Advanced Solid Tumors; K. M. Bell-McGuinn, et al.; Abstract 2485; Poster Discussion Session; June 3, 2013; 8:00 a.m.-11:45 a.m.
ABT-806
A phase I and Biodistribution Study of ABT-806i, an 111 Iindium-Labeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806; H.K. Gan, et al.; Abstract 2520; Poster Discussion Session; June 4, 2013; 8:00 a.m.-12:30 p.m.
About ABT-199
ABT-199 is a selective inhibitor of B-cell lymphoma-2 (BCL-2) proteins. The B-cell lymphoma 2 gene prevents apoptosis of some cells including lymphocytes, and can be highly expressed in cancers in the lymph nodes, spleen, and other organs of the immune system. As a BH3-mimetic, ABT-199 is designed to block the function of the BCL-2 protein by restoring the communication system that tells cancer cells to self-destruct. Jointly developed by AbbVie and Genentech, the companies are pioneering BCL-2 research with ABT-199, which is currently in Phase 1/1b clinical trials for the treatment of CLL, the most common leukemia in the United States, and several other cancers.
The U.S. Food and Drug Administration (FDA) recently accepted AbbVie's amended clinical trial protocols for studies of ABT-199 in patients with CLL and enrollment for ABT-199 clinical trials in CLL, NHL and multiple myeloma has been re-instated. AbbVie and Genentech expect to move ABT-199 into later-stage clinical trials in the near future.
About Elotuzumab
Elotuzumab is a humanized monoclonal antibody that targets against CS1, a cell-surface glycoprotein that is highly expressed on multiple myeloma cells. Two Phase 3 studies of elotuzumab in combination with lenalidomide and low-dose dexamethasone at a dose of 10 mg/kg are ongoing in patients with newly-diagnosed (ELOQUENT1) and relapsed/refractory multiple myeloma (ELOQUENT2). Elotuzumab is being jointly developed by AbbVie and Bristol-Myers Squibb.
About ABT-888 (Veliparib)
Veliparib is an investigational oral poly (adenosine diphosphate [ADP]–ribose) polymerases (PARPs) inhibitor being evaluated in multiple tumor types. PARP is a naturally occurring enzyme in the body that repairs damage to DNA, and contributes to chemotherapy resistance in cancer cells. Discovered and developed by AbbVie researchers, ABT-888 (veliparib) is being developed to increase the effectiveness of common DNA-damaging therapies like chemotherapy or radiation. Veliparib is currently being studied in more than a dozen cancers and tumor types, including Phase 2 studies in a variety of cancers, including breast, ovarian, non small-cell lung and gastrointestinal cancers.
About ABT-806
ABT-806i is an immunoradiopharmaceutical formed by labeling monoclonal antibody ABT‑806 with indium 111 (111In). The antibody portion of the radiopharmaceutical, ABT-806, is a humanized antibody specific for an epitope of EGFR; and epitope that is exposed in deletion variant EGFRde2-7 (EGFRvIII) or when wild-type EGF receptors are amplified, overexpressed, or activated. This epitope provides for the opportunity to use ABT-806i as an imaging agent for the identification and characterization of solid tumor malignancies expressing EGFR, including those expressing deletion variant EGFRde2-7. ABT-806 was in-licensed by AbbVie from Life Science Pharmaceuticals.